Advanced Micro Devices
AMD
ASML Holding
ASML
Meta Platforms
META
Cisco
CSCO
Taiwan Semiconductor
TSM
US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 2.010
- +0.020+1.01%
Close Dec 27 16:00 ET
- 1.960
- -0.050-2.49%
Post 20:01 ET
37.90MMarket Cap-2.14P/E (TTM)
2.010High1.900Low120.84KVolume2.000Open1.990Pre Close239.73KTurnover1.02%Turnover RatioLossP/E (Static)18.86MShares2.55052wk High2.32P/B23.76MFloat Cap0.46052wk Low--Dividend TTM11.82MShs Float184.000Historical High--Div YieldTTM5.53%Amplitude0.420Historical Low1.983Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Chemomab Therapeutics Stock Forum
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
Chemomab Therapeutics presented Phase 2 SPRING trial data for CM-101 in primary sclerosing cholangitis (PSC) at AASLD The Liver Meeting® 2024.
The trial, involving 76 patients, tested two doses (10 mg/kg and 20 mg/kg) administered every three weeks over 15 w...
1 min ago
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of Cm-101 Phase 2 Results in Primary Sclerosing Cholangitis at Aasld the Liver Meeting® 2024
Resale of up to 8.1 Mln Adss
No comment yet